Published in Cancer Epidemiol Biomarkers Prev on December 01, 2005
Communicating the results of clinical research to participants: attitudes, practices, and future directions. PLoS Med (2008) 3.05
Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review. Health Psychol (2009) 1.58
Distress among women receiving uninformative BRCA1/2 results: 12-month outcomes. Psychooncology (2009) 1.17
Colorectal cancer risk perception on the basis of genetic test results in individuals at risk for Lynch syndrome. J Clin Oncol (2009) 0.96
Melanoma genetic testing, counseling, and adherence to skin cancer prevention and detection behaviors. Cancer Epidemiol Biomarkers Prev (2013) 0.94
Is no news good news? Inconclusive genetic test results in BRCA1 and BRCA2 from patients and professionals' perspectives. Hered Cancer Clin Pract (2010) 0.94
Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families. BMC Cancer (2006) 0.90
Short-term psychological impact of the BRCA1/2 test result in women with breast cancer according to their perceived probability of genetic predisposition to cancer. Br J Cancer (2013) 0.90
Introducing genetic testing for cardiovascular disease in primary care: a qualitative study. Br J Gen Pract (2014) 0.89
Analysis of BRCA1 variants in double-strand break repair by homologous recombination and single-strand annealing. Hum Mutat (2012) 0.88
Development and validation of a brief screening instrument for psychosocial risk associated with genetic testing: a pan-Canadian cohort study. BMJ Open (2013) 0.87
Self-reported mammography use following BRCA1/2 genetic testing may be overestimated. Fam Cancer (2012) 0.87
Factors associated with intrusive cancer-related worries in women undergoing cancer genetic risk assessment. Fam Cancer (2008) 0.77
Improved health perception after genetic counselling for women at high risk of breast and/or ovarian cancer: construction of new questionnaires-an Italian exploratory study. J Cancer Res Clin Oncol (2015) 0.75
A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. J Clin Oncol (2011) 5.67
The emergence of an ethical duty to disclose genetic research results: international perspectives. Eur J Hum Genet (2006) 5.34
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol (2006) 4.92
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada. PLoS Med (2010) 3.85
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. J Clin Oncol (2006) 2.81
Job strain and risk of acute recurrent coronary heart disease events. JAMA (2007) 2.61
Household transmission of the 2009 pandemic A/H1N1 influenza virus: elevated laboratory‐confirmed secondary attack rates and evidence of asymptomatic infections. Clin Infect Dis (2010) 2.41
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
Genetic analysis of patients with the Saethre-Chotzen phenotype. Am J Med Genet (2002) 2.17
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. J Obstet Gynaecol Can (2007) 2.09
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev (2011) 1.99
A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet (2005) 1.96
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet (2013) 1.88
Wage losses in the year after breast cancer: extent and determinants among Canadian women. J Natl Cancer Inst (2008) 1.80
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev (2007) 1.75
Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Hum Genet (2006) 1.70
Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology (2008) 1.65
Health status in survivors of cancer in childhood and adolescence. Qual Life Res (2006) 1.62
Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev (2003) 1.60
Effort-reward imbalance at work and recurrent coronary heart disease events: a 4-year prospective study of post-myocardial infarction patients. Psychosom Med (2011) 1.56
Genetic discrimination and life insurance: a systematic review of the evidence. BMC Med (2013) 1.55
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) 1.51
Conceptualization and sources of costs from breast cancer: findings from patient and caregiver focus groups. Psychooncology (2005) 1.49
Work absence after breast cancer diagnosis: a population-based study. CMAJ (2005) 1.43
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2010) 1.41
Educational and social late effects of childhood cancer and related clinical, personal, and familial characteristics. Cancer (2005) 1.40
Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. Am J Hum Genet (2013) 1.39
Preoperative bowel preparation in gynecologic oncology: a review of practice patterns and an impetus to change. Int J Gynecol Cancer (2011) 1.39
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res (2012) 1.38
Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG. Gynecol Oncol (2013) 1.36
Health-related quality of life among child and adolescent survivors of childhood cancer. J Clin Oncol (2006) 1.36
Mutations in C5ORF42 cause Joubert syndrome in the French Canadian population. Am J Hum Genet (2012) 1.32
BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Res (2005) 1.31
Non-compliance with drug treatment and reading difficulties with regard to prescription labelling among seniors. Gerontology (2002) 1.30
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2013) 1.29
Contagious period for pandemic (H1N1) 2009. Emerg Infect Dis (2010) 1.28
Not working 3 years after breast cancer: predictors in a population-based study. J Clin Oncol (2005) 1.28
Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev (2009) 1.25
Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res (2006) 1.23
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res (2011) 1.22
Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations. J Clin Virol (2009) 1.20
Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium. J Clin Endocrinol Metab (2004) 1.19
Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. J Med Genet (2006) 1.17
Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2012) 1.17
Impact of a multipronged education strategy on antibiotic prescribing in Quebec, Canada. Clin Infect Dis (2011) 1.15
Evaluation of serological diagnostic methods for the 2009 pandemic influenza A (H1N1) virus. Clin Vaccine Immunol (2011) 1.14
Practice effect and test-retest reliability of attentional and executive tests in middle-aged to elderly subjects. Clin Neuropsychol (2004) 1.13
Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec. Mol Genet Metab (2012) 1.13
Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol (2005) 1.13
Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol (2006) 1.11
Determinants of discontinuation of new courses of antihypertensive medications. J Clin Epidemiol (2002) 1.09
Near-infrared spectroscopy as an alternative to the Wada test for language mapping in children, adults and special populations. Epileptic Disord (2007) 1.08
The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion. Cell Cycle (2013) 1.08
Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev (2005) 1.08
Indicators for evaluating cancer organizations' support services: performance and associations with empowerment. Cancer (2014) 1.08
Couples who get closer after breast cancer: frequency and predictors in a prospective investigation. J Clin Oncol (2005) 1.07
Factors associated with an individual's decision to withdraw from genetic testing for breast and ovarian cancer susceptibility: implications for counseling. Genet Test (2007) 1.07
Tremor-ataxia with central hypomyelination (TACH) leukodystrophy maps to chromosome 10q22.3-10q23.31. Neurogenetics (2010) 1.06
Psychological distress and physical health in the year after diagnosis of DCIS or invasive breast cancer. Breast Cancer Res Treat (2009) 1.05
Impact of prior authorization for asthma medications on the use of emergency health services: a retrospective cohort study among newly diagnosed patients with asthma. Clin Ther (2010) 1.05
Hereditary multiple intestinal atresia: thirty years later. J Pediatr Surg (2004) 1.04
Sanfilippo syndrome type C: mutation spectrum in the heparan sulfate acetyl-CoA: alpha-glucosaminide N-acetyltransferase (HGSNAT) gene. Hum Mutat (2009) 1.03
Out-of-pocket costs for accessing adjuvant radiotherapy among Canadian women with breast cancer. J Clin Oncol (2011) 1.03
First-line therapy in ovarian cancer trials. Int J Gynecol Cancer (2011) 1.03
Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families. J Hum Genet (2008) 1.02
Results of a genome-wide linkage analysis in prostate cancer families ascertained through the ACTANE consortium. Prostate (2003) 1.01
Randomized clinical trial on cognitive therapy for depression in women with metastatic breast cancer: psychological and immunological effects. Palliat Support Care (2006) 1.01
Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2010) 1.01
Investigating the construct validity of intolerance of uncertainty and its unique relationship with worry. J Anxiety Disord (2006) 1.00
Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. Am J Clin Pathol (2008) 1.00
A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. Hum Mol Genet (2013) 1.00
Use of health care services by survivors of childhood and adolescent cancer in Canada. Cancer (2006) 0.99
Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy. Int J Oncol (2006) 0.99
Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Mol Genet Metab (2007) 0.98
GATA factors and the nuclear receptors, steroidogenic factor 1/liver receptor homolog 1, are key mutual partners in the regulation of the human 3beta-hydroxysteroid dehydrogenase type 2 promoter. Mol Endocrinol (2005) 0.98
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat (2012) 0.98
LRPPRC mutations cause a phenotypically distinct form of Leigh syndrome with cytochrome c oxidase deficiency. J Med Genet (2011) 0.98
Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation. Oncotarget (2014) 0.98
The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2006) 0.96
Generalized anxiety disorder: a comparison of symptom change in adults receiving cognitive-behavioral therapy or applied relaxation. J Consult Clin Psychol (2012) 0.95
Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles? Cancer Res (2004) 0.94
Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families. Hum Genet (2005) 0.94